Order Article Reprints

Tong YT, Lai Z, Katz MHG, Prakash LR, Wang H, Chatterjee D, Kim M, Tzeng C-WD, Lee JE, Ikoma N, et al. Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Cancers. 2023; 15(9):2608. https://doi.org/10.3390/cancers15092608

Tong, Yi Tat, Zongshan Lai, Matthew H. G. Katz, Laura R Prakash, Hua Wang, Deyali Chatterjee, Michael Kim, Ching-Wei D. Tzeng, Jeffrey E. Lee, Naruhiko Ikoma, and et al. 2023. "Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy" Cancers 15, no. 9: 2608. https://doi.org/10.3390/cancers15092608

Tong, Y. T., Lai, Z., Katz, M. H. G., Prakash, L. R., Wang, H., Chatterjee, D., Kim, M., Tzeng, C.-W. D., Lee, J. E., Ikoma, N., Rashid, A., Wolff, R. A., Zhao, D., Koay, E. J., Maitra, A., & Wang, H. (2023). Prognosticators for Patients with Pancreatic Ductal Adenocarcinoma Who Received Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Therapy and Pancreatectomy. Cancers, 15(9), 2608. https://doi.org/10.3390/cancers15092608